MacroGenics | MGNX - Cost Of Sales


MacroGenics reported $49.7M in Cost of Sales for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 245.42M
Cash and Equivalent USD 130.69M
Cost of Sales USD 49.7M
Current Assets USD 204.94M
Current Liabilities USD 39M
Debt USD 37.25M
EBIT USD -35.34M
EBITDA USD -33.44M
Employees 339
EPS Earnings Per Share USD -0.57
Equity Capital and Reserves USD 46.62M
Gross Profit on Sales USD -27.46M
Interest Expense on Debt USD 802K
Interest Income USD 1.41M
Loan Capital USD 70.26M
Market Capitalization USD 124.9M
Net Income USD -36.25M
Operating Expenses USD 59M
Operating Profit USD -36.76M
Ordinary Share Capital USD 63.21M
Pre-Tax Profit USD -36.15M
Sales Revenues USD 22.24M
Selling and Administration Expenses USD 9.3M
Stock USD 9.28M
Trade Creditors USD 4.66M
Trade Debtors USD 12.53M

Cost Of Sales Change Date
AbbVie USD 4.35B 344M Jun/2025
Amgen USD 3.01B 406M Jun/2025
AstraZeneca USD 2.47B 232M Jun/2025
Biogen USD 605M 24.3M Jun/2025
Bristol-Myers Squibb USD 3.37B 339M Jun/2025
Daiichi Sankyo JPY 92.35B 1.99B Jun/2025
Eli Lilly USD 2.45B 223.6M Jun/2025
Genmab DKK 57M 15M Jun/2025
Geron USD 1.19M 16K Jun/2025
Gilead Sciences USD 1.5B 39M Jun/2025
J&J USD 7.6B 304M Jun/2025
MacroGenics USD 49.7M 44.21M Jun/2025
Merck USD 2.82B 53M Jun/2025
Pfizer USD 4.99B 2.4B Jun/2025
Regeneron Pharmaceuticals USD 530.2M 264.7M Jun/2025
Roche Holding CHF 4.13B 393.5M Dec/2024
Xencor USD 61.66M 50.95M Jun/2025